Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey.
Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey.
Pulm Pharmacol Ther. 2020 Jun;62:101920. doi: 10.1016/j.pupt.2020.101920. Epub 2020 May 13.
Cannabinoids and the endocannabinoid system significantly contributes to the airway inflammation. Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) are two main enzymes responsible for the metabolism of the endocannabinoids anandamide (AEA) and 2-arachydonoyl glycerol (2-AG), respectively. In the present study, we aimed to investigate the effects of local and systemic FAAH and MAGL inhibitor treatments in experimental airway inflammation and tracheal hyperreactivity in mice. Airway inflammation was induced by intranasal (i.n.) lipopolysaccharide (LPS) application (60 μl; 0,1 mg/ml in PBS) to mice and the control group received PBS. Systemic (intraperitoneal (i.p.)) or local (i.n.) FAAH inhibitor URB597 and MAGL inhibitor JZL184 treatments were administered 1h before LPS/PBS application. Fourty 8 h after LPS/PBS application, tracheas were removed to assess airway reactivity, and the lungs and bronchoalveolar lavage (BAL) fluids were isolated for histopathological evaluation, cytokine and endocannabinoid measurements. LPS application lead to an increase in 5-hydroxytryptamine (5-HT) contractions in isolated tracheal rings while carbachol contractions remained unchanged. The increased 5-HT contractions were prevented by both systemic and local URB597 and JZL184 treatments. Systemic treatment with URB597 and JZL184, and local treatment with JZL184 reduced peribronchial and paranchymal inflammation in the LPS group while i.n. application of URB597 worsened the inflammation in the lungs. Systemic URB597 treatment increased lung AEA level whereas it had no effect on 2-AG level. However, JZL184 treatment increased 2-AG level by either systemic or local application, and also elevated AEA level. Inflammation-induced increase in neutrophil numbers was only prevented by systemic URB597 treatment. However, both URB597 and JZL184 treatments abolished the increased TNF-α level either they are administered systemically or locally. These results indicate that FAAH and MAGL inhibition may have a protective effect in airway inflammation and airway hyperreactivity, and therefore their therapeutic potential for airway diseases should be further investigated.
大麻素和内源性大麻素系统显著促进气道炎症。脂肪酸酰胺水解酶 (FAAH) 和单酰基甘油脂肪酶 (MAGL) 是分别负责代谢内源性大麻素花生四烯酸乙醇酰胺 (AEA) 和 2-花生四烯酰甘油 (2-AG) 的两种主要酶。在本研究中,我们旨在研究局部和全身 FAAH 和 MAGL 抑制剂治疗对实验性气道炎症和小鼠气管高反应性的影响。气道炎症通过鼻内 (i.n.) 应用脂多糖 (LPS) (60 μl;PBS 中的 0.1 mg/ml) 诱导小鼠,对照组接受 PBS。在 LPS/PBS 应用前 1 小时,给予全身 (腹腔内 (i.p.)) 或局部 (i.n.) FAAH 抑制剂 URB597 和 MAGL 抑制剂 JZL184 治疗。在 LPS/PBS 应用后 40 小时,取出气管以评估气道反应性,并分离肺和支气管肺泡灌洗液 (BAL) 以进行组织病理学评估、细胞因子和内源性大麻素测量。LPS 应用导致分离气管环中的 5-羟色胺 (5-HT) 收缩增加,而卡巴胆碱收缩保持不变。全身和局部 URB597 和 JZL184 治疗均可预防这种 5-HT 收缩增加。全身给予 URB597 和 JZL184 治疗,以及局部给予 JZL184 治疗可减轻 LPS 组的支气管周围和肺实质炎症,而 i.n. 给予 URB597 可加重肺部炎症。全身 URB597 治疗增加了肺 AEA 水平,但对 2-AG 水平没有影响。然而,JZL184 治疗无论是全身还是局部应用都增加了 2-AG 水平,并升高了 AEA 水平。只有全身 URB597 治疗才能预防炎症诱导的中性粒细胞数量增加。然而,URB597 和 JZL184 治疗无论是全身还是局部应用都消除了增加的 TNF-α 水平。这些结果表明,FAAH 和 MAGL 抑制可能对气道炎症和气道高反应性具有保护作用,因此应进一步研究其治疗气道疾病的潜力。